Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PTCT – PTC Therapeutics Inc

Float Short %

12.21

Margin Of Safety %

-17

Put/Call OI Ratio

0.35

EPS Next Q Diff

-1.29

EPS Last/This Y

13.55

EPS This/Next Y

-9.55

Price

77.25

Target Price

81.86

Analyst Recom

2

Performance Q

35.65

Relative Volume

0.52

Beta

0.49

Ticker: PTCT




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-10PTCT72.510.370.2711040
2025-11-11PTCT73.860.371.7211006
2025-11-12PTCT750.360.8911017
2025-11-13PTCT74.950.360.0311050
2025-11-14PTCT75.270.360.0811079
2025-11-17PTCT75.620.350.1311467
2025-11-18PTCT76.590.330.5512396
2025-11-19PTCT75.60.331.4112445
2025-11-20PTCT76.410.330.8312473
2025-11-21PTCT78.490.330.0712575
2025-11-24PTCT79.820.340.0011609
2025-11-25PTCT82.960.340.2411697
2025-11-26PTCT86.230.340.1311747
2025-12-01PTCT79.210.332.9812628
2025-12-02PTCT78.490.360.2213323
2025-12-03PTCT75.80.360.1313309
2025-12-04PTCT77.820.350.1513283
2025-12-05PTCT77.250.350.0313303
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-10PTCT72.4818.3-815.88.16
2025-11-11PTCT73.82-42.5-815.19.45
2025-11-12PTCT74.96-42.5-815.49.45
2025-11-13PTCT74.92-42.5-816.69.45
2025-11-14PTCT75.27-42.5-816.39.45
2025-11-17PTCT75.58-42.5-816.39.45
2025-11-18PTCT76.69-42.5-815.59.45
2025-11-19PTCT75.60-42.5-817.79.45
2025-11-20PTCT76.45-31.7-815.78.79
2025-11-21PTCT78.51-31.7-814.58.79
2025-11-24PTCT79.80-31.7-815.38.79
2025-11-25PTCT82.93-31.7-813.58.79
2025-11-26PTCT86.25-31.7-813.58.79
2025-12-01PTCT79.20-31.7-822.78.79
2025-12-02PTCT78.50-31.7-817.38.79
2025-12-03PTCT75.76-31.7-819.38.79
2025-12-04PTCT77.85-24.9-814.48.82
2025-12-05PTCT77.25-24.9-817.28.82
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-10PTCT-7.32-2.0710.17
2025-11-11PTCT-7.33-2.0710.17
2025-11-12PTCT-7.33-2.0710.85
2025-11-13PTCT-7.33-2.0710.85
2025-11-14PTCT-7.33-2.0710.83
2025-11-17PTCT-7.71-0.6410.84
2025-11-18PTCT-7.70-0.6410.83
2025-11-19PTCT-7.75-0.6410.83
2025-11-20PTCT-7.75-0.6410.83
2025-11-21PTCT-7.75-0.6410.80
2025-11-24PTCT-8.193.7310.80
2025-11-25PTCT-8.463.7310.80
2025-11-26PTCT-8.463.7312.21
2025-12-01PTCT-11.893.8512.21
2025-12-02PTCT-11.893.8512.21
2025-12-03PTCT-11.893.8512.21
2025-12-04PTCT-11.983.8512.21
2025-12-05PTCT-11.983.8512.21
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

0.2

Avg. EPS Est. Current Quarter

-0.43

Avg. EPS Est. Next Quarter

-1.08

Insider Transactions

-11.98

Institutional Transactions

3.85

Beta

0.49

Average Sales Estimate Current Quarter

236

Average Sales Estimate Next Quarter

194

Fair Value

63.99

Quality Score

95

Growth Score

36

Sentiment Score

18

Actual DrawDown %

11.7

Max Drawdown 5-Year %

-73.8

Target Price

81.86

P/E

9.03

Forward P/E

PEG

P/S

3.49

P/B

P/Free Cash Flow

8.8

EPS

8.56

Average EPS Est. Cur. Y​

8.82

EPS Next Y. (Est.)

-0.73

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

42.25

Relative Volume

0.52

Return on Equity vs Sector %

-509.5

Return on Equity vs Industry %

-494.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.65

EBIT Estimation

-817.2
PTC Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 939
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
stock quote shares PTCT – PTC Therapeutics Inc Stock Price stock today
news today PTCT – PTC Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTCT – PTC Therapeutics Inc yahoo finance google finance
stock history PTCT – PTC Therapeutics Inc invest stock market
stock prices PTCT premarket after hours
ticker PTCT fair value insiders trading